About this trial
The goal of this observational study is to evaluate whether polygenic risk score (PRS) assessment can help predict the onset of epithelial ovarian cancer in women aged over 18, comparing those with a histologically confirmed diagnosis of epithelial ovarian or fallopian tube cancer (cases) to women with no personal history of ovarian cancer (controls). The main questions it aims to answer are:
* Is there an association between PRS and the presence of epithelial ovarian cancer? * Can PRS improve the prediction of ovarian cancer risk when adjusted for other clinical factors?
Researchers will compare PRS values between cases and controls to see if higher PRS percentiles are associated with an increased risk of ovarian cancer.
Participants will:
* Complete a questionnaire on socio-economic status, lifestyle, and dietary habits. * Undergo blood sampling, for the analysis of BRCA1-2, PALB2, RAD51C, RAD51D pathogenic variants. * Undergo PRS analysis.
Eligibility criteria
Qualifiers
For cases: women with a first-time diagnosis of histologically confirmed epithelial ovarian or fallopian tube cancer.
For Controls women with no concomitant or past OC diagnosis.
Disqualifiers
For both cases and controls: the presence of concurrent malignancies other from OC.
Trial design
Treatments tested in this trial
- Polygenic Risk Score
- Biopsy on normal contralateral ovary
- Pharmacogenetic profiles
- Full-Field Optical Coherence Tomography (FF-OCT), combined with Dynamic Cell Imaging (Van Gogh System) on detecting ovarian cancer lesions from tissue samples
Treatment groups
Sponsors and collaborators
Catholic University of the Sacred Heart
Lead sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Collaborator